Inoxgen (Nitric Oxide)

Nitric oxide released from Inoxgen activates soluble guanylate cyclase in pulmonary vascular smooth muscle, raising cyclic GMP levels. This biochemical cascade leads to smooth muscle relaxation, vasodilation of the pulmonary arteries, and a reduction in pulmonary vascular resistance.

The dose of Inoxgen is individualized and set by the prescribing clinician based on the patient’s age, weight, severity of pulmonary hypertension, and response to therapy. Specific dosing regimens are not standardized and must follow the prescriber’s instructions.

The safety of Inoxgen in pregnancy and lactation has not been definitively established. It is classified as unknown for pregnancy, and healthcare providers should weigh potential benefits against risks before prescribing to pregnant or nursing individuals.

To order Inoxgen, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details, and any necessary import documentation.

Inoxgen delivers nitric oxide directly to the lungs, offering rapid and targeted vasodilation, whereas other agents such as phosphodiesterase‑5 inhibitors act systemically. This inhaled approach can provide quicker hemodynamic effects with potentially fewer systemic side effects, but it requires specialized delivery equipment.

Inoxgen should be stored at room temperature, kept upright in its original cylinder, and protected from excessive heat and direct sunlight. Ensure the cylinder is secured to prevent movement that could affect the gas integrity.

Inoxgen is administered via inhalation using a calibrated delivery system that mixes the gas with the patient’s breathing circuit. The prescriber determines the flow rate and duration, and healthcare staff monitor the patient’s respiratory and hemodynamic status throughout treatment.

Serious risks include severe hypotension, methemoglobinemia, pulmonary edema, bronchospasm, and allergic reactions such as anaphylaxis. Patients should be closely monitored for signs of these events, and immediate medical intervention should be initiated if they occur.

Inoxgen is contraindicated in patients with known hypersensitivity to nitric oxide, those with methemoglobin reductase deficiency, and individuals with severe hypotension or unstable cardiovascular status unless under specialist supervision.